| C27 | Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084 | E-poster | PrEP |
| B53 | Prevalence of depression among postpartum women on Isoniazid-Preventive Therapy and Efavirenz-based treatment for HIV'an exploratory objective of the IMPAACT P1078 randomized trial | E-poster | Pregnancy (clinical management issues and pharmacokinetics) |
| B53 | Adverse perinatal outcomes associated with timing of initiation of antiretroviral therapy: systematic review and meta-analysis | E-poster | Pregnancy (clinical management issues and pharmacokinetics) |
| B53 | Comparable pregnancy outcomes for HIV-uninfected and HIV-infected women on antiretroviral treatment in Kenya | E-poster | Pregnancy (clinical management issues and pharmacokinetics) |
| B53 | A comparative multi-country analysis of the impact of COVID-19 on HIV services for pregnant and breastfeeding women and their infants | E-poster | Pregnancy (clinical management issues and pharmacokinetics) |
| D97 | Perceived acceptability of broadly neutralizing antibodies (bnAbs) for HIV prevention among young men who have sex with men at risk for HIV infection in the United States | E-poster | Pre-exposure prophylaxis |
| D97 | Acceptability of and preferences for next generation PrEP products among young men who have sex with men | E-poster | Pre-exposure prophylaxis |
| D97 | Pre-exposure prophylaxis as an additional HIV prevention choice in Uganda - the role of a responsive supply chain system | E-poster | Pre-exposure prophylaxis |
| D97 | Challenges of recommencing HIV pre-exposure prophylaxis (PrEP) use during the COVID-19 pandemic | E-poster | Pre-exposure prophylaxis |
| D97 | Assessing level of exposure and predictors of intention to use HIV pre-exposure prophylaxis among adolescent girls and young women exposed to Jipende JiPrEP campaign in Kisumu, Kenya | E-poster | Pre-exposure prophylaxis |